West Point Pharmaceuticals announced that the company recently received the "Notice of Approval of Supplementary Application for Drugs" for Resmin Oral Solution containing tartaric acid lis issued by the National Medical Products Administration. This pharmaceutical is used to treat symptoms of mild to moderate Alzheimer's disease.
西点药业：重酒石酸利斯的明口服溶液获药品补充申请批准
West Point Pharmaceuticals: Resmin Oral Solution containing tartaric acid lis is approved for supplementary drug application.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated